Clinical efficacy of robotic pancreaticoduodenectomy in treatment of periampullary carcinoma
Journal Title: Chinese Journal of Clinical Research - Year 2024, Vol 37, Issue 4
Abstract
"<b>Objective</b> To investigate the clinical application and efficacy of Da Vinci robotic assisted pancreaticoduodenectomy (RPD) in treatment of periampullary carcinoma（PAC）. <b>Methods</b> The clinical data of 8 patients with PAC (5 cases of pancreatic head adenocarcinoma, 2 cases of duodenal adenocarcinoma, and 1 case of adenocarcinoma of the lower bile duct) admitted to Yancheng First Peoples Hospital from December 2021 to June 2023 were retrospectively analyzed. There were 4 males and 4 females, aged (63±10) years，and all of them were treated with RPD. The patients status during and after operation, and at follow-up were observed, with the follow-up time until June 2023. <b>Results</b> Eight patients successfully completed RPD, without any conversion to open surgery. The surgery time was (358±68) min, and the intraoperative blood loss was (240±112) mL. Only one patients received intraoperative allogeneic blood transfusion. All patients had negative pathological margins and achieved R0 resection. The time to gastric tube extraction, time to initial diet intake, time for getting out of bed and postoperative hospital stay of 8 patients were (3.6±1.1), (2.8±0.6), (2.6±0.4) and (20.8±4.2) days, respectively. There was no secondary operation and no perioperative death. Six cases had perioperative complications (some cases complicated with multiple complications), including 4 cases of mild pancreatic leakage, 1 case of biliary leakage, 3 cases of pleural or abdominal effusion,1 case of intestinal retention,and 1 case of gastric obstruction, all of which were cured after symptomatic conservative treatment. All 8 cases received a median follow-up of 10 months, with 2 cases experiencing tumor recurrence and metastasis, and 6 cases without recurrence and metastasis . One case died due to pulmonary embolism,and 7 cases entered the adjuvant chemotherapy procedure after surgery and all survived, with good living conditions. <b>Conclusion</b> RPD is safe and feasible for the treatment of PAC,and can be applied individually and reasonably.However, long-term prognosis evaluation requires large-size, high-quality clinical studies."
Authors and Affiliations
LI Zuoan*, ZHANG Xiaoyan, XU Liqun, XU Yonghua, AN Hongyin, ZHA Wenzhang
Keywords
Related Articles
- EP ID EP734609
- DOI 10.13429/j.cnki.cjcr.2024.04.012
- Views 36
- Downloads 0
Risk factors and predictive efficacy of anastomotic fistula after radical right hemicolectomy
Objective To explore the risk factors for the occurrence of anastomotic fistula after radical right hemicolectomy, and to further assess the predictive efficacy of related factors. Methods A total of 467 patients who und...
Research progress of fibroblast growth factor receptor in gastric cancer
The incidence and mortality of gastric cancer are in the forefront of the tumor, and the prognosis is poor, especially in the middle and advanced stage. Even with comprehensive treatment, the 5- year survival is very lo...
Construction of early screening model of lower extremity atherosclerosis in patients with type 2 diabetes mellitus
Objective To analyze the influencing factors of femoral artery intima-media thickness (IMT) in patients with type 2 diabetes mellitus (T2DM) and to establish a screening model for lower extremity atherosclerosis disease...
Feasibility and clinical value of deep learning reconstruction in accelerated MRI of shoulder
Objective To investigate the feasibility and clinical value of the deep learning reconstruction (DLR) algorithm in enhancing image quality and reducing scan time in shoulder MRI. Methods Fifty patients suspected of hav...
Clinical value of multiple hematological markers to predict infection after hepatic carcinectomy
"Objective To investigate the predictive value of multiple hematological markers in postoperative infection after hepatic carcinectomy, such as neutrophil to lymphocyte ratio (NLR) and monocyte to lymphocyte ratio (MLR)....